The estimated Net Worth of Abigail L. Jenkins is at least $8.7 Mille dollars as of 30 September 2022. Abigail Jenkins owns over 16,129 units of Gamida Cell Ltd stock worth over $8,702 and over the last 2 years Abigail sold GMDA stock worth over $0.
Sign up
Abigail Jenkins GMDA stock SEC Form 4 insiders trading
Abigail has made over 1 trades of the Gamida Cell Ltd stock since 2022, according to the Form 4 filled with the SEC. Most recently Abigail bought 16,129 units of GMDA stock worth $25,000 on 30 September 2022.
The largest trade Abigail's ever made was buying 16,129 units of Gamida Cell Ltd stock on 30 September 2022 worth over $25,000. On average, Abigail trades about 4,032 units every 0 days since 2022. As of 30 September 2022 Abigail still owns at least 266,129 units of Gamida Cell Ltd stock.
You can see the complete history of Abigail Jenkins stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Abigail Jenkins's mailing address?
Abigail's mailing address filed with the SEC is C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN, NJ, 07059.
Insiders trading at Gamida Cell Ltd
Over the last 3 years, insiders at Gamida Cell Ltd have traded over $0 worth of Gamida Cell Ltd stock and bought 85,483 units worth $132,499 . The most active insiders traders include Stephen T Wills, Robert I Blum e Jeremy Blank. On average, Gamida Cell Ltd executives and independent directors trade stock every 0 days with the average trade being worth of $699. The most recent stock trade was executed by Stephen T Wills on 30 September 2022, trading 9,677 units of GMDA stock currently worth $14,999.
What does Gamida Cell Ltd do?
gamida cell is a leader in cellular and immune therapeutics, committed to changing the treatment paradigm for patients with cancer and rare genetic diseases. we are building a broad pipeline based on our proprietary nam technology platform. our lead program, nicord, is in phase 3 development for allogeneic bone marrow transplantation and was granted breakthrough therapy designation by the fda.
What does Gamida Cell Ltd's logo look like?
Complete history of Abigail Jenkins stock trades at Aquestive Therapeutics Inc e Gamida Cell Ltd
Gamida Cell Ltd executives and stock owners
Gamida Cell Ltd executives and other stock owners filed with the SEC include:
-
Julian Adams,
Chief Executive Officer, Director -
Ronit Simantov,
Chief Medical Officer -
Joshua Hamermesh,
Chief Business Officer -
Shai Lankry,
Chief Financial Officer -
Thomas Klima,
Chief Commercial Officer -
Dr. Julian Adams Ph.D.,
CEO & Director -
Dr. Ronit Simantov M.D.,
Chief Medical Officer -
Joshua D. Hamermesh MBA,
Chief Bus. Officer -
Dr. Jas Uppal,
Chief Regulatory & Quality Officer -
Shai Lankry CPA, M.B.A.,
Chief Financial Officer -
Jaren Madden,
Vice President of Investor Relations and Corporate Communications -
Michael Perry,
Non-Executive Independent Director -
Kenneth Moch,
Non-Executive Independent Director -
Ofer Gonen,
Non-Executive Independent Director -
Nurit Benjamini,
Non-Executive Independent Director -
stephen Wills,
Independent Director -
Shawn Tomasello,
Independent Director -
David Fox,
Independent Director -
Jas Uppal,
Chief Regulatory and Quality Officer -
Tracey Lodie,
Chief Scientific Officer -
Tzvi Palash,
Chief Operating Officer -
Robert Blum,
Non-Executive Independent Chairman of the Board -
Joshua F. Patterson,
Gen. Counsel -
Naftali Brikashvili CPA,
Sr. VP Fin. & Operations -
Matthew Metivier,
VP of Human Resource -
Paul Nee,
VP of Marketing -
Michele Ilene Korfin M.B.A., R.Ph.,
Chief Operating & Chief Commercial Officer -
Jeremy Blank,
Director -
Naama Halevi Davidov,
Director -
Anat Cohen Dayag,
Director -
Michele Ilene Korfin,
COO/CHIEF COMMERCIAL OFFICER -
Ivan M. Borrello,
-
Abigail L. Jenkins,
President and CEO -
Joshua F. Patterson,
GENERAL COUNSEL -
Mary Theresa Coelho,
Chief Financial Officer